Inhibikase Therapeutics, Inc. (IKT) DCF Valuation

Inhibikase Therapeutics, Inc. (IKT) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Inhibikase Therapeutics, Inc. (IKT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Save time and improve precision with our (IKT) DCF Calculator! Utilizing real data from Inhibikase Therapeutics, Inc. and customizable assumptions, this tool enables you to forecast, analyze, and value (IKT) like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1.1 .7 3.1 .1 .3 .3 .4 .4 .5 .6
Revenue Growth, % 0 -37.79 343.92 -96.02 111.03 16.55 16.55 16.55 16.55 16.55
EBITDA -5.7 -2.8 -14.8 -18.1 -19.9 -.3 -.4 -.4 -.5 -.6
EBITDA, % -507.52 -403.52 -476.23 -14680.72 -7643.91 -100 -100 -100 -100 -100
Depreciation 5.7 2.8 14.8 .0 .2 .2 .3 .3 .4 .4
Depreciation, % 507.52 403.52 476.23 5.45 68.1 74.71 74.71 74.71 74.71 74.71
EBIT -11.4 -5.6 -29.5 -18.1 -20.1 -.3 -.4 -.4 -.5 -.6
EBIT, % -1015.04 -807.05 -952.47 -14686.17 -7712.01 -100 -100 -100 -100 -100
Total Cash .0 14.0 40.8 23.1 13.3 .2 .3 .3 .4 .4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .1 .0 .0
Account Receivables, % 0 0 3.55 32.31 0
Inventories .0 .0 .1 1.1 .0 .1 .1 .1 .1 .1
Inventories, % 0 0 3.45 905.39 0 20.69 20.69 20.69 20.69 20.69
Accounts Payable 1.0 1.7 1.1 1.2 .6 .3 .3 .4 .4 .5
Accounts Payable, % 89.22 246.35 35.15 932.58 248.28 84.87 84.87 84.87 84.87 84.87
Capital Expenditure .0 .0 .0 -.2 .0 -.1 -.1 -.1 -.1 -.1
Capital Expenditure, % 0 0 0 -197.06 -5.47 -21.09 -21.09 -21.09 -21.09 -21.09
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -11.4 -5.7 -29.6 -18.0 -20.1 -.3 -.4 -.4 -.5 -.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -4.7 -2.2 -15.7 -19.1 -19.3 -.6 -.1 -.2 -.2 -.2
WACC, % 9.53 9.53 9.53 9.53 9.53 9.53 9.53 9.53 9.53 9.53
PV UFCF
SUM PV UFCF -1.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -3
Present Terminal Value -2
Enterprise Value -3
Net Debt -9
Equity Value 6
Diluted Shares Outstanding, MM 5
Equity Value Per Share 1.06

What You Will Get

  • Real IKT Financial Data: Pre-filled with Inhibikase Therapeutics' historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See IKT's intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Inhibikase Therapeutics, Inc. (IKT).
  • Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to fit your analysis.
  • Real-time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow evaluations.
  • User-Friendly Dashboard: Intuitive charts and summaries to help you visualize your valuation findings.
  • Designed for All Skill Levels: An accessible and straightforward layout tailored for investors, CFOs, and consultants alike.

How It Works

  • Step 1: Download the prebuilt Excel template with Inhibikase Therapeutics, Inc. (IKT) data included.
  • Step 2: Explore the pre-filled sheets to familiarize yourself with the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Inhibikase Therapeutics, Inc. (IKT) intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose This Calculator for Inhibikase Therapeutics, Inc. (IKT)?

  • User-Friendly Interface: Crafted for both novice and experienced users.
  • Customizable Parameters: Adjust inputs effortlessly to tailor your analysis.
  • Real-Time Updates: Observe immediate changes to Inhibikase's valuation as you modify inputs.
  • Preloaded Data: Comes equipped with Inhibikase's latest financial figures for swift evaluations.
  • Preferred by Experts: Utilized by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Investors: Accurately assess Inhibikase Therapeutics, Inc.'s (IKT) fair value before making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Inhibikase Therapeutics, Inc. (IKT).
  • Consultants: Efficiently modify the template for valuation reports tailored to clients in the biotech sector.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
  • Educators: Employ it as a teaching resource to illustrate valuation techniques in the biotechnology industry.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Inhibikase Therapeutics, Inc. (IKT).
  • Real-World Data: Inhibikase’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
  • Key Ratios: Integrated analysis for assessing profitability, efficiency, and leverage specific to Inhibikase Therapeutics, Inc. (IKT).
  • Dashboard with Visual Outputs: Visual representations including charts and tables for clear, actionable insights.

No products were found matching.